Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Parke (NPI 1265638746)

Field	Value
Entity Type	Individual
Organization	David Parke
Address	7760 France Ave S
City	Minneapolis
State	MN
ZIP	55435
Taxonomy	Ophthalmology Physician
NPI Enumerated	June 22, 2007

Payer Source	Total Paid
Medicare	$4.8M
Medicaid	$0

Key Findings

The provider’s Medicare billing is dominated by intravitreal anti-VEGF therapy and associated injection procedures: J0178 (4.2K claims, $691 avg paid/claim, $2.9M revenue, 61.3%) and J2777 (33.3K claims, $29 avg paid/claim, $965.7K revenue, 20.2%) are the two largest revenue drivers, and 67028 (2.8K claims, $97 avg paid/claim, $267.9K revenue, 5.6%) captures the separate injection procedure billing. This mix—high-volume injectable drug codes plus an isolated injection procedure code—points to a practice focused on retinal injections for medical retinal disease rather than predominantly office-based diagnostic visits.

Revenue concentration is extreme: the top 3 Medicare codes account for 87.1% of this provider’s total Medicare revenue, and total Medicare revenue on file is $4.8M. That concentration indicates financial dependence on a small set of high-revenue drug and procedure codes, making enrollment and reimbursement changes for these agents potentially material to the practice’s revenue.

Payer mix is effectively single-payer Medicare: the profile shows $4.8M in total Medicare revenue and no Medicaid billing on file, so this clinician operates without measurable Medicaid revenue in the dataset. Analysts should treat this entity as Medicare-centric when modeling patient mix, access, or contract leverage.

Competitive standing is strong nationally for key retinal services: J0178 ranks #52 of 3204 providers nationally (98th percentile; notably above typical national volume) and 92134 (retinal OCT imaging) registers 3.7K claims and $107.9K revenue (2.3%) while ranking #178 of 26868 providers nationally (99th percentile; extreme outlier). Those ranks indicate this provider is a high-volume national outlier for aflibercept administration and retinal imaging relative to peers.

The provider’s practice appears procedure-heavy with limited E/M revenue: 92012 (intermediate established exam) and 92014 (comprehensive established exam) together total 1,447 claims and about $107.8K in revenue (92012: 863 claims, $55.2K, 1.2%; 92014: 584 claims, $52.6K, 1.1%). The low share of eye exam revenue versus injection/drug reimbursement underscores a workflow oriented around in-office injections and imaging rather than new-patient evaluations.

There is a marked contrast between drug volume and unit reimbursement: J2777 shows very high claim volume (33.3K claims) with low average payment ($29 avg paid/claim) generating $965.7K, whereas J0178 has far fewer claims (4.2K) but a much higher per-claim payment ($691 avg paid/claim) generating $2.9M. This pattern suggests the provider bills both high-frequency, low-unit-price drug administrations and lower-frequency, high-unit-price administrations, which affects inventory, billing complexity, and revenue volatility.

Use of biosimilars and alternatives is present but limited relative to aflibercept: Q5128 (ranibizumab-eqrn biosimilar) tallied 380 claims and $81.7K revenue (1.7%) and J9035 (bevacizumab) shows 625 claims and $34.4K revenue (0.7%). Both codes rank in ranges described as typical or unremarkable for national peers (Q5128 ranks #251 of 373 providers nationally; J9035 ranks #182 of 1852 providers nationally), indicating modest adoption of lower-cost alternatives compared with reliance on aflibercept.

The provider has long tenure in Medicare enrollment (NPI enumerated 2007-06-22, ~19 years ago), which is consistent with the established, high-volume injection and imaging patterns observed. Long-standing enrollment combined with the heavy procedure and drug mix suggests an established referral pipeline and clinical focus on medical retina care rather than a recently scaled-up practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

16 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	4,240	$690	$2.9M
J2777	Injection, faricimab‑svoa, 0.1 mg	33,300	$30	$965.7K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,760	$100	$267.9K
J2778	Injection, ranibizumab, 0.1 mg	1,250	$180	$230.2K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,720	$30	$107.9K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	380	$220	$81.7K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	860	$60	$55.2K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	580	$90	$52.6K
J9035	Injection, bevacizumab, 10 mg	630	$60	$34.4K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	150	$110	$17.1K

Showing 1–10 of 16

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

David Parke — 7 of 16 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

16 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	1	40	580	$690	$743.4K
J2777	2	20	6,120	$30	$411.1K
Q5128	15	20	1,410	$220	$393.8K
J2778	4	20	500	$180	$121K
67028	3	80	420	$90	$64.8K
67108	5	10	10	$1,230	$34.4K
67041	10	10	20	$1,090	$25.1K
J9035	4	40	220	$50	$16.9K
92014	21	830	100	$80	$11.9K
92012	6	200	60	$60	$8.8K

Showing 1–10 of 16

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Parke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Vitreoretinal Surgery PLLC	MN	Ophthalmology Physician	$0	$27.8M
David Williams	MN	Retina Specialist (Ophthalmology) Physician	$5.5M	$0
Sundeep Dev	MN	Ophthalmology Physician	$4.5M	$0
John Davies	MN	Ophthalmology Physician	$3.9M	$0
Polly Quiram	MN	Ophthalmology Physician	$3.7M	$0
Geoffrey Emerson	MN	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
Robert Mittra	MN	Ophthalmology Physician	$3.1M	$0
Abdhish Bhavsar	MN	Retina Specialist (Ophthalmology) Physician	$2.3M	$0
Jacob Jones	MN	Retina Specialist (Ophthalmology) Physician	$2.3M	$0
Yevgeniy Sychev	MN	Retina Specialist (Ophthalmology) Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as David Parke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emergency Physicians Professional Association	MN	Emergency Medicine Physician	$0	$72.7M
Fairview Health Services	MN	General Acute Care Hospital	$0	$17.2M
Professional Resource Network - Prn - Corporation	MN	Home Health Agency	$0	$12.4M
Virtual Radiologic Professionals, LLC	MN	Diagnostic Radiology Physician	$0	$11.3M
Mental Health Systems PC	MN	Psychologist	$0	$11M
Premier Obgyn Of Minnesota PLLC	MN	Obstetrics & Gynecology Physician	$0	$7M
Noran Neurological Clinic P.A.	MN	Specialist	$0	$6M
Nura Surgical Center LLC	MN	Ambulatory Surgical Clinic/Center	$5.3M	$581.7K
Southdale Pediatric Associates, Ltd	MN	Multi-Specialty Clinic/Center	$0	$5.3M
Peter Belin	MN	Ophthalmology Physician	$1.9M	$0

David Parke — Billing Profile & Reimbursement Data

Sign up for David Parke — Billing Profile & Reimbursement Data policy alerts

David Parke — Billing Profile & Reimbursement Data

Sign up for David Parke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References